Want to see NRIX full AI Analyst Report?
NRIX Stock Chart & Stats
$26.88
$0.05(0.21%)
At close: 4:00 PM EDT
$26.88
$0.05(0.21%)
Day’s Range― - ―
52-Week Range$9.71 - $28.23
Previous Close$23.43
Volume1.28M
Average Volume (3M)1.76M
Market Cap
$2.67B
Enterprise Value$2.01B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$65.33M
Price to Earnings (P/E)9.7
Beta1.18
Next Earnings
Feb 17, 2027EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.51
Shares Outstanding109,249,820
10 Day Avg. Volume2,339,787
30 Day Avg. Volume1,757,923
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda6.24
Forecast
1Y Price Target
$34.18Price Target Upside27.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)2.35
Revenue Forecast (FY)$681.80M
Bulls Say, Bears Say
Bulls Say
TTM Revenue And Earnings InflectionThe sharp TTM revenue increase and return to positive operating profit and net income indicate meaningful progress in financial performance. If the improvement persists, it could strengthen internal funding capacity and support continued development of Nurix’s clinical pipeline.
Strong Capitalization And Modest LeverageA large equity base relative to debt gives Nurix financial flexibility while it advances clinical programs and manages development expenses. Modest leverage reduces interest and refinancing pressure, helping the company sustain investment through biotechnology funding cycles.
Recent Positive Cash GenerationThe latest period shows strong conversion of reported earnings into operating and free cash flow, which can improve funding independence and reduce reliance on external capital. This is particularly valuable for a clinical-stage company with substantial research and development needs.
Bears Say
History Of Persistent LossesSeveral years of operating and net losses demonstrate that the recent earnings improvement has not yet established a proven long-term profit record. Continued historical volatility raises the possibility that future results may again depend on uneven collaboration or milestone-related revenue.
Unclear Profitability QualityInconsistent margin data makes it harder to assess the underlying economics of Nurix’s current earnings and whether they can persist. Without clear profitability measures, confidence is lower that the latest improvement reflects durable operating performance rather than reporting or timing effects.
Dependence On Partner Pipeline TimingNurix’s collaboration-driven model ties important revenue opportunities to partners’ clinical, regulatory, and commercialization progress. Delays or uneven advancement can make revenue lumpy and reduce management’s control over the timing of milestone payments and future royalties.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $9.71 and its highest was $28.23 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $2.67B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Feb 17, 2027 which is in 122 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Oct 12, 2026. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of -$0.601 by $5.331.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 109,249,820 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of $4.73 in its last earnings report, beating expectations of -$0.601. Following the earnings report the stock price went down -0.135%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.18 (27.16% Upside)
$34.18 (27.16% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 71%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 804.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $528.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.46%
12-Months-Change
Fundamentals
Return on Equity
49.34%
Trailing 12-Months
Asset Growth
128.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX Stock 12 Month Forecast
Average Price Target
$34.18
▲(27.16% Upside)
Technical Analysis
Oric Pharmaceuticals
―
Relay Therapeutics
―
Tango Therapeutics
―
Monte Rosa Therapeutics
―
Odyssey Therapeutics, Inc.
―
Ownership Overview
0.16% Insiders
17.01% Mutual Funds
0.30% Other Institutional Investors
64.88% Public Companies and
Individual Investors